Cognito Therapeutics is pioneering a novel, non-invasive therapy aimed at treating Alzheimer’s disease by evoking specific brain wave activity, particularly gamma waves, which are crucial for cognitive functions such as learning and memory. The therapy utilizes proprietary visual and auditory stimulation to restore normal neuronal activity that is often disrupted in Alzheimer’s patients. Research indicates that enhancing gamma wave activity can lead to significant preservation of brain structure, cognition, and daily functioning. In their Phase 2 OVERTURE trial, patients receiving this treatment demonstrated a remarkable reduction in cognitive decline, daily functional decline, and brain volume loss compared to control groups, with no serious adverse events reported.

The treatment is designed to be convenient and adaptable to patients' lifestyles, allowing them to engage in therapy for one hour each day from the comfort of their homes. The device's stimulation intensity is personalized based on each patient's response, confirmed through EEG evaluations. With over 40,000 treatment sessions completed across various clinical studies, Cognito's approach has shown promising results in slowing the progression of Alzheimer’s disease while maintaining a strong safety profile. The company is also exploring the potential of this technology for other neurodegenerative diseases, further expanding its impact on brain health.

United States

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. 

Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Cognito Therapeutics

Company Details